Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant CAPOX Plus Pucotenlimab Combined With Selective Radiotherapy Versus CAPOX Combined With Selective Radiotherapy in Patients With Locally Advanced Rectal Cancer：A Multicenter, Phase III, Randomized Clinical Trial

NCT07528209 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07528209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07528209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant CAPOX Plus Pucotenlimab Combined With Selective Radiotherapy Versus CAPOX Combined With Selective Radiotherapy in Patients With Locally Advanced Rectal Cancer：A Multicenter, Phase III, Randomized Clinical Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Recruiting
Start date
April 20, 2026
Completion date
April 20, 2034
Enrollment
556 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pmmr (microsatellite stable rectal cancer), rectal cancer